RxDoctor Payments Data

Frederic Nguyen, MD

Neurology · Richardson, TXNPI 1528293628

Payments from drug & device makers

$394,793in general payments, 2019–2025

Across 1,253 payments — averaging $315.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$150K
  • Otsuka America Pharmaceutical, Inc.$65K
  • Eisai Inc.$46K
  • Pfizer$34K
  • Argenx US, Inc.$31K
  • Biohaven Pharmaceutical Holding Company Ltd.$24K
  • plus $45K from 54 others
$490in research payments, 2019–2025

Across 1 payment — averaging $490.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Avanir Pharmaceuticals, Inc.$490

What the payments were for

  • Consulting fees$37,57310%
  • Speaking & faculty fees$311,91879%
  • Travel & lodging$23,1816%
  • Food & beverage$22,1046%
  • Education$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)327$149,712
Otsuka America Pharmaceutical, Inc.95$64,858
Eisai Inc.63$46,442
Pfizer55$33,812
Argenx US, Inc.59$30,692
Biohaven Pharmaceutical Holding Company Ltd.30$24,119
Corium, LLC25$14,076
Biohaven Pharmaceuticals, Inc.33$12,808
SK Life Science, Inc.40$5,100
UCB, Inc.47$3,568
Lundbeck LLC38$644
Genentech USA, Inc.24$551
Amgen(2 entities)19$533
Acadia Pharmaceuticals Inc25$518
Acorda Therapeutics, Inc29$501
AstraZeneca(2 entities)17$456
Neurocrine Biosciences, Inc.22$437
Teva Pharmaceuticals USA, Inc.16$396
Biogen19$379
EMD Serono, Inc.19$348
Impel Pharmaceuticals Inc.12$345
Upsher-smith Laboratories LLC23$329
Novartis16$304
Sunovion Pharmaceuticals Inc.16$303
Sanofi13$249
Lilly USA, LLC13$247
MDD US Operations, LLC12$206
Avanir Pharmaceuticals, Inc.11$202
Supernus Pharmaceuticals, Inc.18$201
Eli Lilly1$175
TG Therapeutics, Inc.5$128
Penumbra, Inc.1$119
Sumitomo Pharma America, Inc.6$110
Jazz Pharmaceuticals Inc.4$109
Avion Pharmaceuticals6$107
Johnson & Johnson(2 entities)6$99
GE HealthCare4$91
Takeda Pharmaceuticals U.S.A., Inc.3$83
Axsome Therapeutics, Inc.3$82
Bristol Myers Squibb5$82
Ipsen Biopharmaceuticals, Inc3$81
Hospira, Inc.5$81
Averitas Pharma Inc.3$76
Neurelis, Inc.3$73
Currax Pharmaceuticals LLC5$73
Arbor Pharmaceuticals, Inc.4$73
Abbott4$72
GRT US Holding, Inc.4$71
Adamas Pharmaceuticals, Inc.3$59
Assertio Therapeutics, Inc.3$55
Catalyst Pharmaceuticals, Inc.2$50
CSL Behring3$49
Aquestive Therapeutics, Inc.3$49
Merz Pharmaceuticals, LLC2$48
Medtronic2$37
Impel Pharmaceuticals LLC2$30
Mallinckrodt Enterprises LLC2$30
Amneal Pharmaceuticals LLC2$29
Boston Scientific1$26
Collegium Pharmaceutical, Inc.2$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$394,793 in reported general payments places this provider in the 90th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$385,403
Medicare patients
458
Services billed
28,307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole17$30,657
NamzaricMemantine Hcl/Donepezil Hcl13$21,603
Memantine Hcl156$5,162
Rasagiline Mesylate14$5,045
Galantamine Hbr35$4,569
Gabapentin89$2,280
Ropinirole Hcl55$2,259
Carbidopa-LevodopaCarbidopa/Levodopa60$2,185
Primidone91$2,166
Oxcarbazepine38$2,036
Sumatriptan Succinate14$1,682
Carbidopa-Levodopa ErCarbidopa/Levodopa29$1,591
Pregabalin19$1,194
Levetiracetam34$1,136
Donepezil Hcl115$1,128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$64,858$30,65717 claims
AbbVieNamzaric$149,712$21,60313 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$29$83116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,246 neurology providers in Texas.

Other neurology in Richardson

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →